Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schuster

Showing results (521-530 of 630) with videos related to

Pageof 63
Sort By:
Blood Advances|December 10, 2024
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysisPeter A Riedell, Connor B Grady, Loretta J Nastoupil, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Haematologica|December 17, 2016
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 studyGilles Salles, Stephen J Schuster, Sven de Vos, et al.
JAMA Dermatology|April 2, 2025
Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary SyndromeOmar Elghawy, Jonathan H Sussman, Austin G Yang, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
American Journal of Hematology|February 19, 2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemiaAnthony R Mato, Kenneth A Foon, Tatyana Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Pageof 63

Showing results (521-530 of 630) with videos related to

Sort By:
Pageof 63
Blood Advances|December 10, 2024
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysisPeter A Riedell, Connor B Grady, Loretta J Nastoupil, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
Haematologica|December 17, 2016
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 studyGilles Salles, Stephen J Schuster, Sven de Vos, et al.
JAMA Dermatology|April 2, 2025
Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary SyndromeOmar Elghawy, Jonathan H Sussman, Austin G Yang, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
American Journal of Hematology|February 19, 2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemiaAnthony R Mato, Kenneth A Foon, Tatyana Feldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Pageof 63